0

Evaluation of the Pharmacokinetics, Safety and Clinical Efficacy of Ziprasidone for the Treatment of Schizophrenia and Bipolar Disorder

Roberto Mandrioli, Michele Protti, Laura Mercolini

Expert Opin Drug Metab Toxicol. 2015 Jan;11(1):149-74.

PMID: 25483358

Abstract:

Introduction:
Multiple strategies exist for the pharmacological treatment of schizophrenia and related disorders. In the last 20 years, several 'new' compounds have been introduced, called 'atypical antipsychotics', which have higher efficacy and better tolerability than first-generation neuroleptics. Among them, ziprasidone (ZPR) is currently finding widespread use, and it has also been shown to be active as an augmenter in bipolar disorder therapy.
Areas covered:
This review aims to provide the latest information on ZPR, an 'atypical' agent for the pharmacological therapy of schizophrenia and bipolar disorder. A literature search has been carried out with the keywords 'ziprasidone', 'schizophrenia', 'psychosis', 'bipolar', 'pharmacokinetics' and 'clinical trials'. In this process, particular attention has been paid to the drug pharmacokinetic characteristics and its safety in clinical use.
Expert opinion:
ZPR shares most advantages and disadvantages with other atypical antipsychotics. However, it can be useful for its low tendency to cause metabolic syndrome and hyperprolactinaemia, especially in patients suffering from excess weight, hyperlipidaemia, diabetes or who have suffered from hyperprolactinaemia when using other antipsychotics. However, there are serious doubts as to whether ZPR should be administered to patients suffering from arrhythmias or QTc prolongation, and even more for administration to bipolar patients undergoing polypharmacy with antidepressants.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP1159977044 Ziprasidone Related Compound D Ziprasidone Related Compound D 1159977-04-4 Price
qrcode